88,995 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by RFG Advisory LLC

RFG Advisory LLC bought a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 88,995 shares of the company's stock, valued at approximately $3,927,000. RFG Advisory LLC owned approximately 0.12% of SpringWorks Therapeutics as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SWTX. Huntington National Bank boosted its stake in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after acquiring an additional 192 shares in the last quarter. AlphaQuest LLC raised its position in shares of SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after purchasing an additional 414 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in shares of SpringWorks Therapeutics in the fourth quarter worth $45,000. State of Wyoming lifted its position in shares of SpringWorks Therapeutics by 39.5% in the fourth quarter. State of Wyoming now owns 1,530 shares of the company's stock valued at $55,000 after acquiring an additional 433 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in SpringWorks Therapeutics in the 4th quarter valued at about $56,000.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Barclays reiterated an "equal weight" rating and issued a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. HC Wainwright reiterated a "neutral" rating and set a $47.00 price objective (down from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. TD Cowen reaffirmed a "hold" rating and set a $47.00 price target (down from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th. Guggenheim reiterated a "neutral" rating and issued a $47.00 price target on shares of SpringWorks Therapeutics in a report on Monday, May 12th. Finally, Evercore ISI cut SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $52.57.

SpringWorks Therapeutics Price Performance

SWTX stock remained flat at $46.80 during mid-day trading on Friday. 3,119,418 shares of the company's stock traded hands, compared to its average volume of 2,296,686. The stock's fifty day moving average is $43.41 and its two-hundred day moving average is $43.52. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The firm has a market cap of $3.53 billion, a P/E ratio of -13.45 and a beta of 0.77.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The business had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. On average, equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.